Burning Point
Latest round
- Series B
Last raised
- Jun 2023
Total raised
- Undisclosed
Investors
- 4
About Burning Point
Established in 2019 and based in Nanjing, China, Burning Point operates as a new drugs developer that provides slow and controlled release formulations, complex injectables, and improved new drugs and innovative drugs. The company cooperates with China Pharmaceutical University, Nanjing University of Traditional Chinese Medicine and Nanjing University of Technology, etc. More than 50% employees of the core research team have PhD and master's degrees. And it has a 3000 square meter pharmacy research laboratory. In November 2022, the company awarded the title of high-tech enterprise., Ltd. The company provides pharmaceutical R&D services, including chemical API process, Chinese medicine and natural drug, and preparation process development, consistency evaluation, analysis and testing, clinical research, and registration filing. Its products include slow and controlled release formulations, complex injectables, and improved new drugs and innovative drugs. The company generates revenue by providing slow and controlled release formulations, complex injectables, and improved new drugs and innovative drugs. The company will use the funds to build an industrial base for injections and conduct preclinical research on improved new drugs.
Who invested in Burning Point
4 investors across 2 rounds
See all investors in Burning Point
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Burning Point
Who invested in Burning Point?
Burning Point has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Burning Point raised?
Burning Point has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Burning Point last raise money?
Burning Point's most recent round on record is a Series B, in Jun 2023.
What does Burning Point do?
Established in 2019 and based in Nanjing, China, Burning Point operates as a new drugs developer that provides slow and controlled release formulations, complex injectables, and improved new drugs and innovative drugs.
Where is Burning Point headquartered?
Burning Point is headquartered in Nanjing, China.
Which VCs invest in companies like Burning Point?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Burning Point's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Burning Point? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.